Idiopathic pulmonary fibrosis (IPF)
Conditions
Interventions
None listed
Sponsors
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
Center for Genomic Medicine, Kyoto University. Department of Respiratory Medicine, Tenri Hospital. Department of Respiratory Medicine, Kobe City Medical Center General Hospital. Department of Respiratory Medicine, Kobe City Medical Center West Hospital. Department of Respiratory Medicine, Takatsuki Red Cross Hospital. Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital. Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi National
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with idiopathic pulmonary fibrosis based on guidelines of an official ATS/ERS/JRS/ALAT statement.
Exclusion criteria
Exclusion criteria: (A)Retrospective study; patients who experienced the onset of malignant disease within 3 years from first visit for our hospital. (B)Prospective study; (1) Patients with complication of malignant disease. But the patients who received complete resection or successful remission induction, and survived for more than 3 years without evidence of recurrence are eligible. (2) Patients who have been received more than 10mg/day of prednisolone or antifibrotic agents within 6 months. (3) Patients with acute exacerbation of IPF, respiratory infection, or pneumothorax within 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in the telomere length attrition rate by administration of antifibrotic agent. | — |
Countries
Japan
Contacts
Public ContactTomohiro Handa
Graduate School of Medicine, Kyoto University Department of Respiratory Medicine
Outcome results
None listed